AMP RA/SLE Leadership Center

 描述(由申请人提供)：RFA声明：“AMP RA和狼疮网络(Network)的总体目标是定义共享的和特定于疾病的生物通路，以便确定用于治疗RA、狼疮和相关自身免疫性疾病的相关药物靶点。为了实现这一目标，将建立一个独特和新颖的基础设施，它将使用一种合作的跨学科、综合的团队科学方法来测试高影响力的想法，这些想法将：为对驱动疾病的机制的新的和全面的了解奠定基础；刺激对尖端技术的早期和应用研究；并通过加速发现与自身免疫性疾病有关的疾病途径来推动研究事业。“我们的AMP RA和狼疮网络领导中心(LC)将使所有这些交付成果得以实现。我们LC的目标是建立一个创造性的、灵活的和高度互动的小组，由来自美国各地(14个州的24个机构)和国际上的顶尖科学家组成-每个机构都有重叠的专业知识 基础、临床和转化研究；技术发明、开发和实施；独特的生物信息学和统计方法；以及与生物技术公司、制药行业、疾病基金会、美国国立卫生研究院和学术机构的广泛互动。我们创建了一种分布式领导模式，利用每个参与调查人员和中心的优势，我们相信这种模式是 完成AMP RFA规定的任务所必需的。我们将建立一个功能强大的基础设施，以不仅满足RFA中规定的目标，而且使能够在RA和SLE方面取得真正变革性的发现，并适用于数十种其他自身免疫性和炎症性疾病。非常重要的是，我们的建议不是创建一个将于2019年结束的模式和基础设施，而是利用这一模式建立一个可持续的项目，通过NIH、企业合作伙伴、基金会和慈善机构的资助，加速其他疾病领域的发现。LC包括LC研究协调、管理和统计计划(LCMP)、系统生物学研究小组(SBG)和组织获取研究小组(TRG)，所有这些都是由合格的教师整合和领导的。

 DESCRIPTION (provided by applicant): The RFA states: "The overall goal of the AMP RA and Lupus Network (Network) is to define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of RA, lupus and related autoimmune diseases. Towards achieving this goal, a unique and novel infrastructure will be established, that uses a collaborative trans-disciplinary, integrated team science approach, to test high impact ideas that will: lay the foundation for a new and comprehensive understanding of mechanisms driving disease; stimulate early and applied research on cutting-edge technologies; and, advance the research enterprise by accelerating the discovery of disease pathways involved in autoimmune diseases." Our AMP RA and Lupus Network Leadership Center (LC) will enable all of these deliverables to be met. The goal of our LC is to establish a creative, nimble, and highly interactive group composed of leading scientists from throughout the United States (24 institutions across 14 States) and internationally - each with overlapping expertise in basic, clinical and translational research; technology invention, development, and implementation; unique bioinformatics and statistical methodology; and extensive interactions with biotechnology companies, pharmaceutical industry, disease foundations, NIH, and academic institutions. We have created a distributive model of leadership that takes advantage of the strengths of each of the participating investigators and centers, a model that we believe is necessary to complete the missions set forth in the AMP RFA. We will build a highly-functional infrastructure to meet not just the goals stated in the RFA, but to enable discoveries to be made that are truly transformative in RA and SLE, and are applicable to dozens of other autoimmune and inflammatory diseases. Very importantly, our proposal is not to create a model and infrastructure that will end in 2019, but rather to leverage this model to build a sustainable program that will accelerate discoveries in other disease areas, through funding from NIH, corporate partners, foundations, and philanthropy. The LC includes an LC Research Coordination, Management and Statistics Program (LCMP), a Systems Biology Research Group (SBG), and a Tissue Acquisition Research group (TRG), all of which are integrated and led by qualified faculty.